The Food and Drug Administration on Friday granted accelerated approval to Amtagvi, an individualized tumor-infiltrating lymphocyte therapy for adults with unresectable or metastatic melanoma whose cancer has progressed after a PD-1 blocking drug and, when appropriate, BRAF-targeted therapy. The FDA approval notice makes lifileucel, Amtagvi’s generic name, the first tumor-derived T-cell therapy approved by the agency and opens a new treatment path for patients whose melanoma has continued to advance after modern immunotherapy.

The approval rests on a single-arm clinical program rather than a randomized comparison. Among 73 patients who received the recommended dose in the primary efficacy population, 31.5% achieved an objective response, including three complete responses and 20 partial responses. The median duration of response had not been reached at 18.6 months of follow-up, and 43.5% of responses had lasted at least 12 months, according to the company’s February 16 announcement. Because the indication was granted under accelerated approval, continued approval may depend on verification of clinical benefit in a confirmatory trial.

A therapy built from the patient’s own tumor

Amtagvi differs fundamentally from conventional drugs and from the engineered CAR-T products already used in several blood cancers. The treatment begins with surgical removal of a piece of a patient’s melanoma. Tumor-infiltrating lymphocytes, or TILs, are isolated from that tissue and expanded outside the body into billions of cells. The resulting individualized product is then returned to the same patient by intravenous infusion.

The FDA’s prescribing information specifies a single dose containing 7.5 billion to 72 billion viable cells. Before the infusion, patients receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine. Beginning three to 24 hours after Amtagvi, patients receive high-dose interleukin-2, or aldesleukin, to support expansion of the infused T cells inside the body. Treatment must occur in an inpatient hospital setting with intensive-care capability available because the regimen can produce severe complications.

The therapeutic idea is decades old: immune cells that have already migrated into a tumor may recognize cancer-specific targets, but there may be too few of them or they may be suppressed by the tumor environment. Removing those cells, expanding them to very large numbers and reinfusing them after lymphodepletion is intended to restore a concentrated antitumor immune response. A 2021 Journal of Clinical Oncology study of an earlier C-144-01 cohort described a centralized 22-day manufacturing process and reported a 36% investigator-assessed response rate among 66 heavily pretreated patients, helping establish the clinical foundation for the later regulatory program.

The pivotal program shows responses after checkpoint failure

The approval addresses a particularly difficult point in melanoma treatment. PD-1 checkpoint inhibitors have transformed care for advanced disease, and patients with BRAF V600 mutations can also receive BRAF and MEK inhibitors. But once melanoma progresses after those therapies, effective options become much more limited. Amtagvi is approved specifically for adults who have already received a PD-1 blocker and, if their tumor carries a BRAF V600 mutation, a BRAF inhibitor with or without a MEK inhibitor.

The larger C-144-01 dataset published in 2022 included 153 patients from consecutive cohorts who had received a median of three prior lines of therapy. In the pooled Phase 2 analysis, the independently reviewed objective response rate was 31.4%, with eight complete responses and 40 partial responses. At a median follow-up of 27.6 months, the median duration of response had not been reached, and 41.7% of responses had persisted for at least 18 months. The study also documented substantial baseline disease burden: more than half of patients had elevated lactate dehydrogenase, and many had already received both PD-1 and CTLA-4 checkpoint therapy.

For the FDA-approved dosing range, the agency focused on a defined efficacy cohort of 73 patients. The American Association for Cancer Research summarized the approval in a February 16 report, noting the 31.5% response rate and the durability signal at 18.6 months. Those results do not establish that Amtagvi improves survival compared with another treatment, which is why the accelerated-approval pathway requires additional evidence. They do show that a meaningful minority of patients with treatment-resistant melanoma can experience measurable tumor shrinkage, sometimes lasting a year or longer.

The risks are substantial and inseparable from the regimen

Amtagvi’s novelty does not make it a low-intensity treatment. The FDA label carries a boxed warning for treatment-related mortality, prolonged severe cytopenia, severe infection, and cardiopulmonary and renal impairment. In the clinical-trial safety population, the label reports treatment-related mortality of 7.5%, including deaths during lymphodepletion, within 30 days of treatment and later in follow-up. Severe infections, bleeding, renal failure, respiratory failure, cardiac events and bone-marrow failure were among the fatal complications described.

Blood-count suppression is also common because patients receive intensive lymphodepleting chemotherapy before the TIL infusion. The prescribing information reports prolonged grade 3 or higher cytopenia or pancytopenia in 45.5% of melanoma patients, while febrile neutropenia occurred in 46.8%. The regimen therefore requires close monitoring, antimicrobial support and access to clinicians experienced in complex oncology and critical care.

Those risks must be weighed against the prognosis of the population for whom Amtagvi is approved. These are patients whose cancers have already progressed despite therapies that represent the backbone of current melanoma treatment. The FDA’s formal approval letter places the indication within the accelerated-approval framework and requires postmarketing work to confirm benefit, reflecting the agency’s judgment that the response data justify access while additional evidence is developed.

A manufacturing and delivery challenge accompanies the science

Unlike a vial that can be stocked on a pharmacy shelf, every Amtagvi dose is unique to one patient. A tumor specimen must be surgically harvested, shipped to a manufacturing facility, processed and expanded, cryopreserved, returned to an authorized treatment center and matched back to the correct patient. Iovance says the commercial product will be produced at its Philadelphia cell-therapy facility and a contract manufacturer, with more than 30 authorized treatment centers prepared at launch to collect tumor tissue and administer therapy.

The individualized process creates practical questions about timing, referral patterns and access. Patients must remain medically stable enough to undergo tumor resection, wait for manufacturing, tolerate lymphodepletion and then receive both the cell infusion and high-dose interleukin-2. That sequence is demanding for people with rapidly progressing metastatic cancer. It also requires coordination among surgeons, medical oncologists, cell-therapy teams, hospitals, laboratories, manufacturers and insurers.

The FDA’s Amtagvi product page identifies the therapy as an autologous product approved on the basis of objective response rate and states that continued approval may be contingent on confirmation of clinical benefit. Iovance says it is conducting the Phase 3 TILVANCE-301 trial as the confirmatory study, testing lifileucel in combination with pembrolizumab against pembrolizumab alone in frontline advanced melanoma.

Cell therapy moves beyond blood cancers

The broader importance of Friday’s decision extends beyond melanoma. Cellular immunotherapy has already produced striking results in leukemias, lymphomas and multiple myeloma, but solid tumors have been much harder to treat with cell-based approaches. Their physical structure, heterogeneous targets and immunosuppressive microenvironments create obstacles that are less prominent in many blood cancers.

TIL therapy approaches the problem differently from engineered CAR-T cells. Instead of genetically modifying a patient’s T cells to recognize a single selected surface target, Amtagvi expands a naturally occurring population of lymphocytes already present within that patient’s tumor. The strategy potentially preserves recognition of multiple tumor antigens, although the effectiveness of the resulting cell population varies from patient to patient.

AACR’s contemporaneous approval summary describes Amtagvi as the first FDA-approved TIL therapy and highlights both the 31.5% response rate and the need for lymphodepletion and aldesleukin support. That combination of individualized manufacturing, intensive conditioning and meaningful response in refractory disease makes the approval a scientific milestone but not a simple treatment breakthrough.

The immediate question for melanoma care is how many eligible patients can safely reach specialized centers and complete the full treatment sequence. The longer-term question is whether the same principle can be extended to other solid tumors. For now, the FDA has accepted evidence that expanded tumor-derived lymphocytes can produce durable responses in some patients with advanced melanoma after checkpoint therapy has failed. That is enough for accelerated approval—and enough to move TIL therapy from decades of experimentation into regulated clinical practice.